COGNOSCI

Cognosci is discovering and developing therapeutic compounds to restore healthy function in these life-threatening diseases. These compounds are small patented synthetic peptides of ten to seventeen amino acids that are based on the multifunctional apoE protein, and have potent in vitro and in vivo anti-inflammatory activity... Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for the treatment of neuroinflammatory diseases including Multiple Sclerosis, Alzheimer's Disease, and brain bleeding events. Each of these disorders has a pharmacogenomic linkage to the apolipoprotein E (APOE) protein and patients with the APOE-ε4 allele typically suffer worse outcomes. Based on these findings, scientists from Duke University created a novel APOE-based compound that had potent anti-inflammatory and neuroprotective activities... The Company has developed a deep pipeline of programs in various stages of development with some programs in preclinical development and..

Also known as: Cognosci, Inc.

Primary location: Park United States